产品名称 | ICAM-1 |
---|
CAS编号和信息 | rp174244 |
---|
UniProtKB | P05362 |
---|---|
Wikipedia | ICAM1 |
Ensembl Gene | ENSG00000090339 |
Entrez Gene | 3383 |
Protein GI | 119604492 |
DrugBank Target | P05362 |
CATH/Gene3D | 2.60.40.10 |
Immunopaedia Search | ICAM-1 |
Ligand ID | 6757 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
名称 | ICAM-1 | ||||||||||
类别 | Peptide | ||||||||||
学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
||||||||||
评价 |
ICAM-1 is a cell-adhesion molecule that is overexpressed on the surface of a number of cancer cells types |
||||||||||
配体家族 | CD molecules (ligands) | ||||||||||
基因/前体 |
|
||||||||||
单字母多肽序列 | QTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPGNWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQGEVTRKVTVNVLSPRYEIVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP | ||||||||||
三字母多肽序列 | |||||||||||
翻译后修饰 | For a complete list of post-translational modifications for this protein, please see the UniProt entry linked to from this ligand page. | ||||||||||
化学修饰 |
1. Pandolfi F, Trentin L, Boyle LA, Stamenkovic I, Byers HR, Colvin RB, Kurnick JT. (1992) Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes.. Cancer, 69 (5): (1165-73). [PMID:1739916] |
2. Huang C, Li N, Li Z, Chang A, Chen Y, Zhao T, Li Y, Wang X, Zhang W, Wang Z et al.. (2017) Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression.. Nat Commun, 8 (13): (14035). [PMID:28102193] |
3. Guo P, Huang J, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA, Auguste DT. (2014) ICAM-1 as a molecular target for triple negative breast cancer.. Proc Natl Acad Sci U S A, 111 (41): (14710-5). [PMID:25267626] |
4. Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG et al.. (2020) Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.. Clin Cancer Res, 26 (22): (6028-6038). [PMID:32917735] |
5. Guo P, Wang B, Liu D, Yang J, Subramanyam K, McCarthy CR, Hebert J, Moses MA, Auguste DT. (2018) Using Atomic Force Microscopy to Predict Tumor Specificity of ICAM1 Antibody-Directed Nanomedicines.. Nano Lett, 18 (4): (2254-2262). [PMID:29505261] |
6. Wang M, Liu W, Zhang Y, Dang M, Zhang Y, Tao J, Chen K, Peng X, Teng Z. (2019) Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.. J Colloid Interface Sci, 538 (13): (630-637). [PMID:30554096] |
7. Wei H, Wang Z, Kuang Y, Wu Z, Zhao S, Zhang Z, Li H, Zheng M, Zhang N, Long C et al.. (2020) Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.. Front Immunol, 11 (13): (573823). [PMID:33072116] |